Novavax
Novavax is a biotech company dedicated to developing innovative vaccines to address global health challenges. Their mission is to leverage science, technology, and their people to create impactful health solutions, with a vision of touching billions of lives and transforming global health. They focus on vaccine technology, strategic partnerships, and a high-impact pipeline to prevent diseases and empower healthier lives.
Industries
Nr. of Employees
Very Large (1000+)
Novavax
700 Quince Orchard Rd, Gaithersburg, Maryland 20878, USA
Patents
Methods and compositions for inducing immune responses against Clostridium difficile
US-11938179-B2
View Details
Methods and compositions for inducing immune responses against Clostridium difficile
US-11938179-B2
View DetailsProducts
Recombinant protein-based COVID-19 vaccine (adjuvanted)
A recombinant protein nanoparticle vaccine formulated with a saponin-derived adjuvant for prevention of COVID-19; authorized for use in select geographies and subject to regulatory filings.
Malaria vaccine using saponin-based adjuvant (partner-developed)
A malaria vaccine developed by external research partners that uses the saponin-derived adjuvant to improve immune response; manufactured and distributed at scale by manufacturing partners.
Seasonal influenza and combination influenza–COVID vaccine candidates
Protein nanoparticle-based seasonal influenza vaccine candidates and combination COVID–influenza formulations under clinical evaluation (including Phase 3 for some candidates).
Recombinant protein-based COVID-19 vaccine (adjuvanted)
A recombinant protein nanoparticle vaccine formulated with a saponin-derived adjuvant for prevention of COVID-19; authorized for use in select geographies and subject to regulatory filings.
Malaria vaccine using saponin-based adjuvant (partner-developed)
A malaria vaccine developed by external research partners that uses the saponin-derived adjuvant to improve immune response; manufactured and distributed at scale by manufacturing partners.
Seasonal influenza and combination influenza–COVID vaccine candidates
Protein nanoparticle-based seasonal influenza vaccine candidates and combination COVID–influenza formulations under clinical evaluation (including Phase 3 for some candidates).
Services
Large‑scale production and supply of a saponin-derived vaccine adjuvant for use in partner and internal vaccine programs.
Partnership models to license platform components (antigen nanoparticle design and adjuvant) and co-develop vaccine candidates with external organizations.
Clinical trial planning and execution capabilities including site engagement, feasibility assessments and multi-phase trial management.
Global medical information contact center and adverse event/product quality reporting infrastructure for marketed and investigational vaccines.
Contracted studies and evaluations using national health datasets (e.g., SNDS) conducted via compliant research laboratories or vendors to inform safety, utilization and regulatory discussions.
Large‑scale production and supply of a saponin-derived vaccine adjuvant for use in partner and internal vaccine programs.
Partnership models to license platform components (antigen nanoparticle design and adjuvant) and co-develop vaccine candidates with external organizations.
Clinical trial planning and execution capabilities including site engagement, feasibility assessments and multi-phase trial management.
Global medical information contact center and adverse event/product quality reporting infrastructure for marketed and investigational vaccines.
Contracted studies and evaluations using national health datasets (e.g., SNDS) conducted via compliant research laboratories or vendors to inform safety, utilization and regulatory discussions.
Expertise Areas
- Vaccine research and development
- Adjuvant development and formulation
- Clinical development and trial management
- Regulatory strategy and global submissions
Key Technologies
- Protein-based nanoparticle vaccines
- Saponin-derived adjuvants
- Recombinant protein antigen expression
- Multivalent antigen display
News & Updates
Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates showed robust immune responses and were well tolerated in an initial cohort of a Phase 3 trial.
The Biologics License Application (BLA) approval for Nuvaxovid™ triggers a milestone payment and ongoing royalties.
The study shows Novavax's COVID-19 vaccine induces lower reactogenicity symptoms compared to mRNA vaccines.
Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates showed robust immune responses and were well tolerated in an initial cohort of a Phase 3 trial.
The Biologics License Application (BLA) approval for Nuvaxovid™ triggers a milestone payment and ongoing royalties.
The study shows Novavax's COVID-19 vaccine induces lower reactogenicity symptoms compared to mRNA vaccines.